Christopher Heery compensation by year
Arcellx Summary Compensation Table · all 3 fiscal years held| Component | FY2022 | FY2023 | FY2024 |
|---|---|---|---|
| Salary | $430,000 | $480,960 | $480,960 |
| Bonus | $249,400 | $192,000 | $302,400 |
| Stock awards | $1,207,161 | $1,537,785 | $2,193,387 |
| Option awards | $3,019,271 | $1,639,028 | $2,547,422 |
| Non-equity incentive | $0 | $0 | $0 |
| Pension and deferred compensation | $0 | $0 | $0 |
| All other | $9,150 | $10,440 | $11,160 |
| Total | $4,914,982 | $3,860,213 | $5,535,329 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Arcellx, Inc. DEF 14A filed April 17, 2025, accession 0001193125-25-084363, and prior-year filings. Open the filing on EDGAR.
Equity holdings
unvested awards at FY2024 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 39,063 | $2,995,741 | — |
| RSU | 33,039 | $2,533,761 | — |
| RSU | 22,556 | $1,729,820 | — |
Per the Outstanding Equity Awards at Fiscal Year-End table in Arcellx, Inc.'s FY2024 proxy; value at the fiscal year-end close, as the company printed it.
Insider transactions since the last proxy
33 Form 4 lines since the FY2024 proxy (filed April 17, 2025)current to 2026-09-24 · updated nightly
| Date | Transaction | Plan | Shares | Price | Held after |
|---|---|---|---|---|---|
| 2026-04-28 | Disposition to the issuer derivative | — | 43,604 | — | 0 |
| 2026-04-28 | Disposition to the issuer derivative | — | 40,000 | — | 0 |
| 2026-04-28 | Disposition to the issuer derivative | — | 60,096 | — | 0 |
| 2026-04-28 | Disposition to the issuer derivative | — | 13,021 | — | 0 |
| 2026-04-28 | Disposition to the issuer derivative | — | 39,194 | — | 0 |
| 2026-04-28 | Grant or award derivative | — | 45,138 | — | 45,138 |
| 2026-04-28 | Disposition to the issuer derivative | — | 45,138 | — | 0 |
| 2026-04-28 | Disposition to the issuer derivative | — | 10,901 | — | 0 |
The 8 most recent of 33 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →
Arcellx’s named executive officers, FY2024
as the company reported each| Named executive officer | Role | FY2024 total |
|---|---|---|
| Rami Elghandour | President, Chief Executive Officer and Chairman | $21,402,668 |
| Michelle Gilson | Chief Financial Officer | $8,248,336 |
| Christopher Heery · this page | Chief Medical Officer | $5,535,329 |
The full Arcellx compensation record
free company briefThis page is one person within Arcellx's record. The company brief lists every named executive, each linking to their own page.
Compensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order Arcellx's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Arcellx's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.
Velarion Pro: every company page, peer tools and exports, one seat